Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
In 1937, when the former Japan Livestock Industry Association became the central organization for the registration of cattle throughout Japan, the breed names of "Japanese Black," "Japanese Polled," and "Japanese Brown" were created in place of the above nine breeds.
== Family and personal life == Dan Ariely was born to Yoram and Dafna Ariely in New York City while his father was studying for an MBA at Columbia University. He has two younger sisters. The family emigrated to Israel when he was three years old. He grew up in Ramat Hasharon. In his senior year of high school, Ariely was active in Hanoar Haoved Vehalomed, an Israeli youth movement affiliated with the Labor Zionist movement. While he was preparing a ktovet esh (fire inscription) for a traditional nighttime ceremony, the flammable materials he was mixing exploded, causing third-degree burns to over 70 percent of his body. In his writings entitled "Painful Lessons", Ariely described his hospitalization and treatments, detailing how that experience led to his research on "how to better deliver painful and unavoidable treatments to patients". Ariely was previously married to Sumedha (Sumi) Gupta in 1998; they have two children. After a second manuscript of his was retracted for containing fabricated data, it was reported that Ariely is seeking political office under the banner of the Pirate Party of Israel.
== Organizations == Gas Safe Register, in the United Kingdom Global Sea Mineral Resources, an underwater mining company Groupe Scolaire La Résidence, a French international school in Casablanca, Morocco
=== May 2003 === In separate incidents, the Royal Military Police declared that Radhi Natna died of a heart attack while in British custody, yet his family reports that he had no heart trouble; and the Black Watch regiment arrested the 17-year-old Ahmad Jabber Kareem Ali in Basra, who then drowned after being ordered to swim across a river despite not being able to swim, according to his friend Ayad Salim Hanoon. Army Reservists abused Prisoners at Camp Bucca, and were later court-martialed. Brigadier General Ennis Whitehead III reported that Master Sergeant Lisa Marie Girman, a state trooper, "repeatedly kick[ed a prisoner] in the groin, abdomen and head, and encouraging her subordinate soldiers to do the same," Lieutenant Colonel Vic Harris reported that Staff Sergeant Scott A. McKenzie who worked at a Pennsylvania Department of Corrections boot-camp-style prison, and Specialist Timothy F. Canjar: held prisoners' legs, encouraged others to then kick them in the groin, stepped on their previously injured arms, and made false sworn statements to the Army Criminal Investigation Division. They received "general under honorable conditions" discharges, were ordered to forfeit two months' salary, and returned to the United States. Sergeant Shawna Edmondson, also involved in the case, received an "other-than-honorable" discharge, after she requested it instead of being court-martialed. Hossam Shaltout said the abuse at Camp Bucca was similar to that at Abu Ghraib prisoner abuse, and that his torture included scorpions placed on his body.
Sources: en.wikipedia.org
artificial gene synthesis A set of laboratory methods used in the de novo synthesis of a gene (or any other nucleic acid sequence) from free nucleotides, i.e. without relying on an existing template strand.
In Germany, democratic socialism became a prominent movement at the end of the 19th century, when the Eisenach's Social Democratic Workers' Party of Germany merged with Lassalle's General German Workers' Association in 1875 to form the Social Democratic Party of Germany. Reformism arose as an alternative to revolution, with leading social democrat Eduard Bernstein proposing the concept of evolutionary socialism. Revolutionary socialists, encompassing multiple social and political movements that may define revolution differently from one another, quickly targeted the nascent ideology of reformism and Rosa Luxemburg condemned Bernstein's Evolutionary Socialism in her 1900 essay titled Social Reform or Revolution? The Social Democratic Party of Germany became the largest and most powerful socialist party in Europe despite being an illegal organisation under Otto von Bismarck's Anti-Socialist Laws until they were repealed in 1890. In the 1893 German federal election, the party gained about 1,787,000 votes, a quarter of the total votes cast according to Engels. In 1895, the year of his death, Engels highlighted The Communist Manifesto's emphasis on winning as a first step the "battle of democracy."
ATS patients experience periodic paralysis, cardiac arrhythmias, and multiple morphological abnormalities that can include cleft or high arched palate, cleft or thin upper lip, flattened philtrum, micrognathia, dental oligodontia, enamel hypoplasia, delayed dentition eruption, malocclusion, broad forehead, wide set eyes, low set ears, syndactyly, clinodactyly, brachydactyly, and dysplastic kidneys. Mutations that disrupt another inwardly rectifying K+ channel Girk2 encoded by KCNJ6 cause Keppen-Lubinsky syndrome which includes microcephaly, a narrow nasal bridge, a high arched palate, and severe generalized lipodystrophy (failure to generate adipose tissue). KCNJ6 is in the Down syndrome critical region such that duplications that include this region lead to craniofacial and limb abnormalities and duplications that do not include this region do not lead to morphological symptoms of Down syndrome. Mutations in KCNH1, a voltage gated potassium channel lead to Temple-Baraitser (also known as Zimmermann- Laband) syndrome. Common features of Temple-Baraitser syndrome include absent or hypoplastic of finger and toe nails and phalanges and joint instability. Craniofacial defects associated with mutations in KCNH1 include cleft or high arched palate, hypertelorism, dysmorphic ears, dysmorphic nose, gingival hypertrophy, and abnormal number of teeth.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.